Related Experiment Video
Updated: Jul 14, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Temozolomide-associated organizing pneumonitis
Fabien Maldonado1, Andrew H Limper, Kaiser G Lim
1Division of Pulmonary and Critical Care Medicine, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. maldonado.fabien@mayo.edu
Abstract:
Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.
Related Concept Videos
Toxoplasmosis
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Other Pulmonary Disorders
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Atypical Pneumonia
Pneumonia II: Pathophysiology